Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Poor penetration of mAbs in solid tumors is explained, in part, by the binding site barrier hypothesis. Following extravasation, mAbs rapidly bind cellular antigens, leading to the observation that, at subsaturating doses, therapeutic antibody in solid tumors localizes around tumor vasculature. Here we report a unique strategy to overcome the binding site barrier through transient competitive inhibition of antibody–antigen binding. The anti-trastuzumab single domain antibody 1HE was identified through in vitro binding assays as a model inhibitor. Coadministration of 1HE did not alter the plasma pharmacokinetics of trastuzumab or ado-trastuzumab emtansine (T-DM1) in vivo. Administration of 1HE alone was rapidly eliminated with a terminal plasma half-life of 1.2 hours, while coadministrations of 1HE with trastuzumab had a terminal half-life of 56 hours. In mice harboring SKOV3 xenografts, coadministration of 1HE with trastuzumab led to significant increases in both penetration of trastuzumab from vasculature and the percentage of tumor area that stained positive for trastuzumab. 1HE coadministered with a single dose of T-DM1 to NCI-N87 xenograft–bearing mice significantly enhanced T-DM1 efficacy, increasing median survival. These results support the hypothesis that transient competitive inhibition can improve therapeutic antibody distribution in solid tumors and enhance antibody efficacy. Significance: This study describes the development of a transient competitive inhibition strategy that enhances the tumor penetration and efficacy of anticancer antibodies. See related commentary by van Dongen, p. 3956
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rudnick, S. I., Lou, J., Shaller, C. C., Tang, Y., Klein-Szanto, A. J. P., Weiner, L. M., Marks, J. D., & Adams, G. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2277 · Cited by 365 · cited 1×
“In addition, trastuzumab has been previously shown to have limited tumor penetration due to highaffinity HER2 binding (13, 18).”
BackgroundEikenes, L., Bruland, Ø. S., Brekken, C., & Davies, C. D. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1472 · Cited by 251
Affinity and Avidity in Antibody-Based Tumor Targeting
Rudnick, S. I., & Adams, G. P. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0627 · Cited by 237
Cited by
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Self-citationOptimizing the safety of antibody–drug conjugates for patients with solid tumours
Tarantino, P., Ricciuti, B., Pradhan, S. M., & Tolaney, S. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00783-w · Cited by 269
Smart drug delivery systems for precise cancer therapy
Wang, X., Li, C., Wang, Y., Chen, H., Zhang, X., Luo, C., Zhou, W., Li, L., Teng, L., Yu, H., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.013 · Cited by 233
Boghaert, E. R., Cox, M. C., & Vaidya, K. S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3236 · Cited by 17
Metadata
- Authors
- Bordeau, B. M., Yang, Y., & Balthasar, J. P.
- Venue
- Cancer Research
- Published
- 2021-03-16
- Volume
- 81
- Issue
- 15
- Pages
- 4145-4154
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W3137681510
- Cited by
- 75
- References
- 3
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy. https://app.cochat.ai/papers/10.1158/0008-5472.can-20-3822
- The paper
- Bordeau, B. M., Yang, Y., & Balthasar, J. P. (2021). Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy. Cancer Research. https://doi.org/10.1158/0008-5472.can-20-3822
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.